– Acthar Gel is the first and only medication in its class of adrenocorticotropic hormone products available in a self-injection device to treat a range of chronic and acute inflammatory and autoimmune conditions 1 – DUBLIN , Aug. 6, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced the availability of the Acthar Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJectTM Injector (herein referred to as "SelfJect"), offering a new administration option for Acthar Gel for appropriate patients with a range of chronic and acute inflammatory and autoimmune conditions. 1 The U.
S. Food and Drug Administration (FDA) previously approved Mallinckrodt's supplemental New Drug Application (sNDA) for SelfJect in February 2024 . Experience the full interactive Multichannel News Release here: https://www.
multivu.com/players/English/9111652-mallinckrodt-selfject-launch/ Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. 1 Acthar Gel is approved by the FDA for the treatment of several autoimmune disorders and medical conditions known to cause inflammation.
1 Please see Indications and Important Safety Information for Acthar Gel below. Acthar Gel is the first and only medication in its class of adrenocorticotropic hormone products available in two forms of administration – multi-dose vial and syringe and SelfJect. 1 The color-coded device is pre-f.